NCT00655655 2024-08-21Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsMayo ClinicPhase 1 Completed96 enrolled
NCT02831179 2017-09-28Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorVanderbilt-Ingram Cancer CenterPhase 1 Withdrawn
NCT01204476 2016-07-15Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaNational Cancer Institute (NCI)Phase 1 Completed27 enrolled
NCT00002947 2014-07-02Indium In 111 Pentetreotide in Treating Patients With Refractory CancerYale UniversityPhase 1 Terminated35 enrolled
NCT00006368 2013-05-01Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerNovartisPhase 1 Completed60 enrolled